Page 141 - MI-2-2

Microbes & Immunity Establishment of a novel anti-human CCR8 monoclonal antibody

5. Conclusion Vivier E. Harnessing innate immunity in cancer therapy.
Nature. 2019;574(7776):45-56.
C Mab-21, established by the CBIS method, is a useful tool
8
for analyzing the hCCR8-positive cells by flow cytometry. doi: 10.1038/s41586-019-1593-5
3. Ribas A, Wolchok JD. Cancer immunotherapy using
Acknowledgments checkpoint blockade. Science. 2018;359(6382):1350-1355.
None. doi: 10.1126/science.aar4060

Funding 4. Karin N. Chemokines and cancer: New immune checkpoints
for cancer therapy. Curr Opin Immunol. 2018;51:140-145.
This research was supported, in part, by the Japan Agency doi: 10.1016/j.coi.2018.03.004
for Medical Research and Development (AMED) under
Grant Nos.: JP24am0521010 (to Y.K.), JP23ama121008 (to 5. van den Bulk J, Verdegaal EM, de Miranda NF. Cancer
Y.K.), JP23bm1123027 (to Y.K.), and JP23ck0106730 (to immunotherapy: Broadening the scope of targetable
Y.K.), and by the Japan Society for the Promotion of Science tumours. Open Biol. 2018;8(6):180037.
(JSPS) Grants-in-Aid for Scientific Research (KAKENHI) doi: 10.1098/rsob.180037
Grant Nos.: 22K06995 (to H.S.) and 22K07224 (to Y. K). 6. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of
response, resistance, and toxicity to immune checkpoint
Conflict of interest blockade. Cell. 2021;184(21):5309-5337.
The authors declare no conflicts of interest. doi: 10.1016/j.cell.2021.09.020

Author contributions 7. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM,
Topalian SL. Antagonists of PD-1 and PD-L1 in cancer
Conceptualization: Mika K. Kaneko, Yukinari Kato treatment. Semin Oncol. 2015;42(4):587-600.
Formal analysis: Tomohiro Tanaka doi: 10.1053/j.seminoncol.2015.05.013
Investigation: Haruto Yamamoto, Yu Kaneko, Tomohiro
Tanaka, Guanjie Li 8. Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor
Methodology: Mika K. Kaneko microenvironment: New mechanisms, potential therapeutic
Writing – original draft: Tomohiro Tanaka strategies and future prospects. Mol Cancer. 2020;19(1):116.
Writing – review & editing: Hiroyuki Suzuki, Yukinari Kato doi: 10.1186/s12943-020-01234-1

Ethics approval and consent to participate 9. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function
of programmed cell death 1 and its ligands in regulating
All animal experiments were approved by the Animal Care autoimmunity and infection. Nat Immunol. 2007;8(3):
and Use Committee of Tohoku University (Permit number: 239-245.
2022MdA-001). doi: 10.1038/ni1443

Consent for publication 10. Yano H, Andrews LP, Workman CJ, Vignali DAA.
Intratumoral regulatory T cells: Markers, subsets and
Not applicable. their impact on anti-tumor immunity. Immunology.
2019;157(3):232-247.
Availability of data
doi: 10.1111/imm.13067
The data from this study are available in the article.
11. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer:
Further disclosure Can Treg cells be a new therapeutic target? Cancer Sci.
2019;110(7):2080-2089.
The paper has been uploaded to a preprint server (DOI:
10.20944/preprints202403.1166.v1). doi: 10.1111/cas.14069
12. Tanaka A, Sakaguchi S. Regulatory T cells in cancer
References immunotherapy. Cell Res. 2017;27(1):109-118.
1. Bruni D, Angell HK, Galon J. The immune contexture and doi: 10.1038/cr.2016.151
Immunoscore in cancer prognosis and therapeutic efficacy. 13. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The
Nat Rev Cancer. 2020;20(11):662-680.
immune contexture in human tumours: impact on clinical
doi: 10.1038/s41568-020-0285-7 outcome. Nat Rev Cancer. 2012;12(4):298-306.
2. Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, doi: 10.1038/nrc3245

Volume 2 Issue 2 (2025) 133 doi: 10.36922/mi.4661